Mateon Therapeutics Inc  

(Public, NASDAQ:MATN)   Watch this stock  
Find more results for NASDAQ:OXGN
+0.008 (2.19%)
Real-time:   2:31PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.35 - 0.37
52 week 0.35 - 1.02
Open 0.36
Vol / Avg. 484,884.00/173,640.00
Mkt cap 9.30M
P/E     -
Div/yield     -
EPS -0.53
Shares 26.54M
Beta 1.53
Inst. own 9%
Nov 14, 2016
Q3 2016 Mateon Therapeutics Inc Earnings Release
Sep 12, 2016
Mateon Therapeutics Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -68.88% -47.18%
Return on average equity -75.05% -50.24%
Employees 13 -
CDP Score - -


701 Gateway Blvd Ste 210
United States - Map
+1-650-6357000 (Phone)
+1-650-6357001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor's blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.

Officers and directors

William D. Schwieterman M.D. Chairman of the Board, President, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Matthew M. Loar CPA Chief Financial Officer, Principal Accounting Officer
Age: 51
Bio & Compensation  - Reuters
David Chaplin Ph.D. Chief Scientific Officer, Director
Age: 59
Bio & Compensation  - Reuters
Simon C. Pedder Ph.D. Director
Age: 55
Bio & Compensation  - Reuters
Donald R. Reynolds Independent Director
Age: 54
Bio & Compensation  - Reuters
Bobby W. Sandage Jr., Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters